Hyperfunctioning thyroid carcinoma: A systematic review

Jun Liu, Ye Wang, Dongzhu Da, Miao ZhengMolecular 2019 · DOI

Abstract

Hyperthyroidism may be caused by the development of primary or metastatic thyroid carcinoma. This systematic review analyzes the pathological characteristics, diagnostic procedures, and treatment strategies for hyperfunctioning thyroid carcinoma (HTC). A PubMed search (1990–2017) identified 42 relevant articles. Findings indicate a significantly higher prevalence of follicular thyroid carcinoma (FTC) in HTC cases compared to general thyroid cancer populations. Primary HTC tumors are notably large (mean 4.25 cm). Diagnosis relies on clinical red flags such as rapid growth and lack of response to radioactive iodine. Surgery remains the primary treatment for localized disease, while radioactive iodine is preferred for metastatic cases.

Introduction

In clinical endocrinology, "hot" nodules—those showing high iodine uptake on scintigraphy—are traditionally considered benign. High levels of thyroid hormones typically suppress Thyroid-Stimulating Hormone (TSH), which should theoretically inhibit the growth of differentiated thyroid cancer cells. However, hyperfunctioning thyroid carcinoma (HTC) presents a biological paradox where the malignancy itself produces excess hormones, leading to thyrotoxicosis. This rarity often leads to clinical oversight, delayed diagnosis, and suboptimal treatment. This review synthesizes data from reported cases to establish clearer diagnostic and management guidelines.

Methods

The authors conducted a systematic literature search of PubMed for studies published between January 1990 and July 2017. Inclusion criteria required evidence that the carcinoma was the source of hormone production. For primary cases, this meant a correlation between tumor size and the "hot" area on scintigraphy or atrophic surrounding tissue. For metastatic cases, persistent hyperthyroidism post-thyroidectomy or high uptake in metastatic lesions was required.

PRISMA flow diagram of the literature search and study selection process.

The initial search yielded 763 articles, which were screened down to 42 relevant papers covering 71 unique cases (43 primary and 28 metastatic).

Results and Data Synthesis

The clinical data extracted from the 42 selected studies provided a comprehensive look at the demographics and pathology of HTC. The study extracted detailed biochemical and pathological markers from each case to identify trends.

Summary of clinical characteristics from selected studies of hyperfunctioning thyroid carcinoma.

Pathological Characteristics

A striking finding was the dominance of Follicular Thyroid Carcinoma (FTC). While FTC typically accounts for only 10% of all thyroid cancers, it represented 46.5% of primary HTC and 71.4% of metastatic HTC cases. This suggests that FTC cells are more likely to retain the biochemical machinery necessary for hormone synthesis compared to Papillary Thyroid Carcinoma (PTC).

Tumor Size and Presentation

HTC tumors are generally large, with a mean size of 4.25 ± 2.12 cm for primary cases. This supports the hypothesis that a "critical mass" of malignant cells is required to produce enough hormone to cause clinical thyrotoxicosis. Patients typically presented with low TSH and elevated T3/T4 levels.

Diagnostic Criteria and Management

The review identifies five critical clinical signs that should prompt a malignancy investigation in patients with "hot" nodules:

  1. Treatment Resistance: No improvement in thyrotoxicosis following radioactive iodine (RAI) treatment.
  2. Ultrasound Features: Presence of hypoechoic solid nodules with microcalcifications.
  3. Rapid Growth: A significant increase in tumor size over a short period.
  4. Physical Fixation: The tumor is fixed to adjacent neck structures.
  5. Invasive Symptoms: Signs of invasion, such as hoarseness or dysphagia.

Treatment Strategies

Surgery (total thyroidectomy) is the first-line treatment for primary HTC. It serves a triple purpose: confirming the diagnosis via pathology, resolving thyrotoxicosis, and providing a curative oncological intervention. For metastatic disease, RAI is the most effective option for managing widespread lesions, often found in the bone, lungs, and liver.

Conclusion

Hyperfunctioning thyroid carcinoma, though rare, challenges the clinical assumption that "hot" nodules are benign. The high prevalence of FTC and the large size of these tumors are key distinguishing features. Clinicians must maintain a high index of suspicion when presented with large, rapidly growing "hot" nodules or those resistant to standard hyperthyroidism treatments.

Summary updated

Abstract

Hyperthyroidism may be caused by the development of primary or metastatic thyroid carcinoma. The aim of the present study was to collect recently reported cases of hyperfunctioning thyroid carcinoma in order to analyze its pathological characteristics, diagnostic procedures and treatment strategies. A PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) search was performed for studies published between January 1990 and July 2017. Full-text articles were identified using the terms, 'hyperfunctioning thyroid carcinoma/cancer', 'malignant hot/toxic thyroid nodule', or 'hyperfunctioning papillary/follicular/Hürthle thyroid carcinoma'. Original research papers, case reports and review articles were included. Among all thyroid carcinoma cases included in the present study, the prevalence of follicular thyroid carcinoma (FTC) was ~10%; however, the prevalence of FTC among hyperfunctioning thyroid carcinomas was markedly higher (46.5% in primary and 71.4% in metastatic disease). The size of hyperfunctioning thyroid tumors was considerably larger compared with that of non-hyperfunctioning thyroid tumors, with a mean size of 4.25±2.12 cm in primary hyperfunctioning thyroid carcinomas. In addition, in cases of metastatic hyperfunctioning thyroid carcinoma, tumor metastases were widespread or large in size. The diagnosis of primary hyperfunctioning thyroid carcinoma is based on the following criteria: i) No improvement in thyrotoxicosis following radioactive iodine (RAI) treatment; ii) development of hypoechoic solid nodules with microcalcifications on ultrasound examination; iii) increase in tumor size over a short time period; iv) fixation of the tumor to adjacent structures; and v) signs/symptoms of tumor invasion. The diagnosis of metastatic hyperfunctioning thyroid carcinoma should be considered in patients suffering from thyrotoxicosis who present with a high number of metastatic lesions (as determined by whole-body scanning), or a history of total thyroidectomy. Surgery is the first-line treatment option for patients with primary hyperfunctioning thyroid carcinoma, as it does not only confirm the diagnosis following pathological examination, but also resolves thyrotoxicosis and is a curative cancer treatment. RAI is a suitable treatment option for patients with hyperfunctioning thyroid carcinoma who present with metastatic lesions.
BibTeX
@inproceedings{liu2019hyperfunctioning,
  author = {Jun Liu and Ye Wang and Dongzhu Da and Miao Zheng},
  title = {{Hyperfunctioning thyroid carcinoma: A systematic review}},
  booktitle = {Molecular},
  year = {2019},
  doi = {10.3892/mco.2019.1927},
}
Figure